HENLIUS (02696) saw its shares climb more than 4% during the early trading session. As of the time of writing, the stock was up 3.48%, trading at HKD 56.5 with a turnover of HKD 12.6525 million. The positive movement follows the company's announcement that it has received approval from the National Medical Products Administration (NMPA) to initiate clinical trials for the combination therapy of injection HLX43, HLX07, and Serplulimab Injection for the treatment of advanced solid tumors. HENLIUS plans to commence a Phase II clinical study of this combination therapy in China once the necessary conditions are met. Public information indicates that HLX43 is an antibody-drug conjugate (ADC) targeting PD-L1, developed by HENLIUS through the conjugation of a novel DNA topoisomerase I inhibitor small molecule toxin-peptide linker, licensed from a third party, with its self-developed anti-PD-L1 antibody; it is intended for the treatment of advanced/metastatic solid tumors. HLX07 is an innovative biologic drug targeting EGFR independently developed by HENLIUS for the treatment of advanced solid tumors. Serplulimab Injection is an innovative anti-PD-1 monoclonal antibody independently developed by HENLIUS.